Latest News
See all →
ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026
Garching / Munich, April 21, 2026 -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it…
Read more
ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference
- Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on 177Lu-edotreotide arm vs. 14.7 months on…
ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026
Garching / Munich, February 25, 2026 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that…
Read more
ITM has one of the deepest, broadest clinical RPT pipelines
Global supply of targeted diagnostic and therapeutic radiopharmaceuticals
Your Career at ITM - Precisely for You
